Home > Insider Trading > Filing (0001209191-17-030977)

Filing Details

Accession Number:: 0001209191-17-030977
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-05-09 16:45:55
Reporting Period:: 2017-05-09

Filing Date:: 2017-05-09
Accepted Time:: 2017-05-09 16:45:55
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1689813	Biohaven Pharmaceutical Holding Co Ltd.	BHVN	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1397906	Albert Cha	C/O Biohaven Pharmaceuticals, Inc. 234 Church Street New Haven CT 06510		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Shares	Acquisiton	2017-05-09	1,506,818	$0.00	1,506,818	No	4	C	Indirect	See footnote
Common Shares	Acquisiton	2017-05-09	470,000	$17.00	1,976,818	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Series A Preferred Shares	Disposition	2017-05-09	1,506,818	$0.00	1,506,818	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect

Footnotes

Represents shares received upon conversion of Series A Preferred Shares.
The shares are held as follows: 1,323,990 shares are held by Vivo Capital Fund VIII, L.P. ("VCF") and 182,828 shares are held by Vivo Capital Surplus Fund VIII, L.P. ("VCSF"). The reporting person is one of the managing members of Vivo Capital VIII, LLC which is the general partner of both VCF and VCSF, and may be deemed to share voting and dispositive power over the shares held by VCF and VCSF. The reporting person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported shares for purposes of Section 16 or for any other purposes.
The shares are held as follows: 412,973 shares are held by VCF and 57,027 shares are held by VCSF. The reporting person is one of the managing members of Vivo Capital VIII, LLC which is the general partner of both VCF and VCSF, and may be deemed to share voting and dispositive power over the shares held by VCF and VCSF. The reporting person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported shares for purposes of Section 16 or for any other purposes.
Effective immediately prior to the closing of the Issuer's initial public offering of its common shares, each Series A Preferred Share automatically converted into one common share of the Issuer. The Series A Preferred Shares had no expiration date.